GLP-1 受体激动剂在糖尿病心肌病中的心血管保护作用: 机制和临床前景

徐晓曼 ,  周蕾

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 729 -734.

PDF (450KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 729 -734. DOI: 10.12092/j.issn.1009-2501.2026.06.002

GLP-1 受体激动剂在糖尿病心肌病中的心血管保护作用: 机制和临床前景

作者信息 +

Cardiovascular protective effects of GLP-1 receptor agonists in dia- betic cardiomyopathy: mechanisms and clinical prospects

Author information +
文章历史 +
PDF (460K)

摘要

糖尿病心肌病(diabetic cardiomyopathy, DCM)是糖尿病患者常见的心血管并发症,尤其 在 2 型糖尿病患者中更为普遍。尽管近年来针对 糖尿病的降糖治疗取得了显著进展,但常规药物 仍难以有效延缓糖尿病心肌病的进展。胰高糖素 样肽-1 受体激动剂(glucagon-like peptide-1 re- ceptor agonists,GLP-1RAs)为新型肠促胰岛素类 药物,不仅用于治疗 2 型糖尿病和肥胖症,还具有 显著的心脏和代谢保护作用,能够降低糖尿病患 者心血管不良事件的发生风险。本文综述了 DCM 的病理生理机制,并重点探讨了 GLP-1RAs 在 DCM 中的降糖外保护作用机制及其最新临床 研究进展。

Abstract

Diabetic cardiomyopathy (DCM) is a common cardiovascular complication in diabetic pa- tients, especially more prevalent in patients with type 2 diabetes mellitus. Although remarkable progress has been made in hypoglycemic therapy for diabetes in recent years, conventional drugs still fail to effectively delay the progression of diabetic cardiomyopathy. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel incretin-based medi- cations, which are not only used for the treatment of type 2 diabetes mellitus and obesity, but also ex- ert significant cardioprotective and metabolic pro- tective effects, and can reduce the risk of adverse cardiovascular events in diabetic patients. This pa- per reviews the pathophysiological mechanisms of DCM, and focuses on the extra-hypoglycemic pro- tective mechanisms of GLP-1RAs in DCM as well as the latest advances in clinical research.

关键词

糖尿病心肌病 / GLP-1 受体激动剂 / 糖尿 病心血管并发症

Key words

diabetic cardiomyopathy / GLP-1 re- ceptor agonists / diabetic cardiovascular complica- tions

引用本文

引用格式 ▾
徐晓曼,周蕾. GLP-1 受体激动剂在糖尿病心肌病中的心血管保护作用: 机制和临床前景[J]. 中国临床药理学与治疗学, 2026, 31(6): 729-734 DOI:10.12092/j.issn.1009-2501.2026.06.002

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Seferović PM, Paulus WJ, Rosano G, et al. Diabetic my- ocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Work- ing Group on Myocardial & Pericardial Diseases[J].Eur J Heart Fail, 2024, 26(9): 1893-1903.

[2]

Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J].Nat Rev Endocrinol, 2016, 12(3): 144-153.

[3]

Jia G, Habibi J, Bostick BP, et al. Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet[J].Hypertension, 2015, 65(3): 531-539.

[4]

Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome[J].Med Clin North Am, 2007, 91(6): 1063-1077.

[5]

Ramasubbu K, Devi Rajeswari V.Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resis- tance induced AGEs on diabetes mellitus and neurode- generative diseases: a perspective review[J].Mol Cell Biochem, 2023, 478(6): 1307-1324.

[6]

Hotamisligil GS, Arner P, Caro JF, et al. Increased adi- pose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance[J].J Clin In- vest, 1995, 95(5): 2409-2415.

[7]

Seale LA, Hashimoto AC, Kurokawa S, et al. Disruption of the selenocysteine lyase-mediated selenium recy- cling pathway leads to metabolic syndrome in mice[J].Mol Cell Biol, 2012, 32(20): 4141-4154.

[8]

Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction[J].Nat Rev Cardiol, 2017, 14(1): 30-38.

[9]

Jia G, Aroor AR, Martinez-Lemus LA, et al. Overnutri- tion, mTOR signaling, and cardiovascular diseases[J].Am J Physiol Regul Integr Comp Physiol, 2014, 307(10): 1198-1206.

[10]

DeMarco VG, Aroor AR, Sowers JR.The pathophysiolo- gy of hypertension in patients with obesity[J].Nat Rev Endocrinol, 2014, 10(6): 364-376.

[11]

Nistala R, Sowers JR. Hypertension: synergy of antihy- pertensives in elderly patients with CKD[J].Nat Rev Nephrol, 2013, 9(1): 13-15.

[12]

Kim JA, Jang HJ, Martinez-Lemus LA, et al. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulat- ed endothelial nitric oxide synthase and vasodilation[J].Am J Physiol Endocrinol Metab, 2012, 302(2): 201-208.

[13]

Zhao Y, Hu X, Zhou L, et al. GLP-1 receptor agonists al- leviate diabetic cardiomyopathy via Sirt3-dependent mitochondrial quality control[J].Cardiovasc Diabetol, 2024, 23(1): 128.

[14]

Falcão-Pires I, Leite-Moreira AF.Diabetic cardiomyopa- thy: understanding the molecular and cellular basis to progress in diagnosis and treatment[J].Heart Fail Rev, 2012, 17(3): 325-344.

[15]

Peng ML, Fu Y, Wu CW, et al. Signaling pathways relat- ed to oxidative stress in diabetic cardiomyopathy[J].Front Endocrinol (Lausanne), 2022, 13: 9077-9157.

[16]

Hashiesh HM, Azimullah S, Nagoor Meeran MF, et al. Cannabinoid 2 receptor activation protects against dia- betic cardiomyopathy through inhibition of AGE/RAGE- induced oxidative stress, fibrosis, and inflammasome activation[J].J Pharmacol Exp Ther, 2024, 391(2): 241-257.

[17]

Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Anti-inflammatory therapy with canakinumab for atherosclerotic disease[J].N Engl J Med, 2017, 377(12): 1119-1131.

[18]

Smith NK, Hackett TA, Galli A, et al. GLP-1: molecular mechanisms and outcomes of a complex signaling sys- tem[J].Neurochem Int, 2019, 128: 94-105.

[19]

Drucker DJ. Mechanisms of action and therapeutic ap- plication of glucagon-like peptide-1[J].Cell Metab, 2018, 27(4): 740-756.

[20]

Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists: beyond their pancreatic effects[J].Front Endocrinol (Lausanne), 2021, 12: 721-135.

[21]

Alobaid SM, Alshahrani RM, Alonazi AS, et al. Liraglu- tide attenuates diabetic cardiomyopathy via the ILK/PI3K/AKT/PTEN signaling pathway in rats with streptozotocin-induced type 2 diabetes mellitus[J].Pharmaceuticals (Basel), 2024, 17(3): 374.

[22]

Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators. Dulaglutide and cardiovascular out- comes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial[J].Lancet, 2019, 394(10193): 121-130.

[23]

Sazgarnejad S, Yazdanpanah N, Rezaei N. Anti-inflam- matory effects of GLP-1 in patients with COVID-19[J].Expert Rev Anti Infect Ther, 2022, 20(3): 373-381.

[24]

Mercadante S, Al-Husinat L.Palliative care in amy- otrophic lateral sclerosis[J].J Pain Symptom Manage, 2023, 66(4): 485-499.

[25]

Mittal M, Siddiqui MR, Tran K, et al. Reactive oxygen species in inflammation and tissue injury[J].Antioxid Redox Signal, 2014, 20(7): 1126-1167.

[26]

Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like pep- tide-1 receptor agonist inhibits asymmetric dimethy- larginine generation in the kidney of streptozotocin-in- duced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression[J].Am J Pathol, 2013, 182(1): 132-141.

[27]

Dowsett L, Higgins E, Alanazi S, et al. ADMA: a key play- er in the relationship between vascular dysfunction and inflammation in atherosclerosis[J].J Clin Med, 2020, 9(9): 3026.

[28]

Pekarova M, Kubala L, Martiskova H, et al. Asymmetric dimethylarginine regulates the lipopolysaccharide-in- duced nitric oxide production in macrophages by sup- pressing the activation of NF-kappaB and iNOS expres- sion[J].Eur J Pharmacol, 2013, 713(1-3): 68-77.

[29]

Luna-Marco C, Iannantuoni F, Hermo-Argibay A, et al. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress[J].Free Radic Biol Med, 2024, 213: 19-35.

[30]

Zhong J, Chen H, Liu Q, et al. GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation[J].J Pharm Anal, 2024, 14(5): 1009-1017.

[31]

Fang P, Ye Z, Li R, et al. Glucagon-like peptide-1 recep- tor agonist protects against diabetic cardiomyopathy by modulating microRNA-29b-3p/SLMAP[J].Drug Des Devel Ther, 2023, 17: 791-806.

[32]

Cai H, Zhou L, Liu J, et al. Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic car- diomyopathy rats[J].Biochem Biophys Res Commun, 2022, 629: 112-120.

[33]

Butler J, Shah SJ, Petrie MC, et al. STEP-HFpEF Trial Committees and Investigators. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials[J].Lancet, 2024, 403(10437): 1635-1648.

[34]

Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER[J].Circulation, 2022, 145(8): 575-585.

[35]

Perkovic V, Tuttle KR, Rossing P, et al. FLOW Trial Com- mittees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes[J].N Engl J Med, 2024, 391(2): 109-121.

[36]

Landin-Olsson M. Effect of liraglutide on beta-cell func- tion in latent autoimmune diabetes in adults: a ran- domized clinical trial[J].Diabetes Care, 2019, 42(7): 1269-1275.

[37]

Wilding JPH.Once-weekly semaglutide in adults with overweight or obesity[J].N Engl J Med, 2021, 384(11): 989-1002.

[38]

Marso SP.Liraglutide and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med, 2016, 375(4): 311-322.

[39]

Verma S. Semaglutide in heart failure with preserved ejection fraction and diabetes: insights from STEP-HF- pEF DM[J].Lancet Diabetes Endocrinol, 2024, 12(7): 489-498.

[40]

Zhang Y, Li J, Chen H, et al. Dual GIP/GLP-1 receptor ag- onist tirzepatide improves cardiac function and my- ocardial metabolism in diabetic cardiomyopathy[J].J Mol Cell Cardiol, 2025, 96: 113245.

[41]

Perkovic V. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J].N Engl J Med, 2019, 380(15): 1407-1419.

[42]

Zander M, Madsbad S, Madsen JL, et al. Effect of 6- week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study[J].Lancet, 2002, 359(9309): 824-830.

[43]

Liu QK.Mechanisms of action and therapeutic applica- tions of GLP-1 and dual GIP/GLP-1 receptor agonists[J].Front Endocrinol (Lausanne), 2024, 15: 1431-292.

[44]

Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Management in CKD[J].Kidney Int, 2022, 102(5):120-127.

[45]

American Diabetes Association. Standards of Medical Care in Diabetes-2023[J].Diabetes Care, 2023, 46(1): 290-294.

基金资助

国家自然科学基金(82370897)

AI Summary AI Mindmap
PDF (450KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉